Dividends & Buybacks ·
Cellyan Biotechnology Co., Ltd filed a proxy statement for an extraordinary general meeting scheduled for September…
HKPDCellyan Biotechnology Co., Ltd
Cellyan Biotechnology Co., Ltd filed a proxy statement for an extraordinary general meeting scheduled for September 21, 2026. The company proposes a one-for-twenty reverse stock split of its Class A and Class B ordinary shares to increase the per-share trading price and regain compliance with Nasdaq's minimum bid price requirement. The consolidation would change the par value from US$0.001 to US$0.02 and reduce authorized share capital from 1,000,000,000 to 50,000,000 shares. Fractional shares will be rounded up to one whole share. The effective date is contingent on Nasdaq confirmation. Cellyan Biotechnology Co., Ltd operates in the biotechnology industry.